CompletedNot Applicable

i-PRF for Temporomandibular Joint Disorders

Turkey (Türkiye)40 participantsStarted 2024-09-02

Plain-language summary

This study will evaluate whether intra-articular injectable platelet-rich fibrin (i-PRF) is more effective than arthrocentesis alone in treating temporomandibular joint (TMJ) disorders. Patients will be randomly assigned to two groups: one receiving arthrocentesis followed by i-PRF injection, and the other undergoing arthrocentesis only. Pain intensity (VAS) and maximum mouth opening will be measured at baseline, 1 week, and 1 months. The goal is to determine if i-PRF provides greater pain relief and functional improvement compared with standard lavage.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients ≥18 years old Diagnosed with temporomandibular joint disorder (TMD) based on clinical and radiological findings Presence of pain, restricted mouth opening, or joint sounds Voluntary participation and signed informed consent Exclusion Criteria: Systemic diseases affecting bone/joint healing (e.g., uncontrolled diabetes, rheumatoid arthritis, osteoporosis) Previous TMJ surgery or intra-articular injection Current pregnancy or breastfeeding Coagulopathy or anticoagulant therapy Allergy to hyaluronic acid (for control group) Inability to attend follow-up visits

What they're measuring

Change in Pain Intensity (VAS score)

Timeframe: Baseline, 1 week, 1 month

Trial details

NCT IDNCT07188974

SponsorEskisehir Osmangazi University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-08-16

View on ClinicalTrials.gov More TMJ Disc Disorder trials